A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

被引：1
|
作者：
Daver, Naval [1 ]
Dao, Kim-Hien [2 ]
Assad, Albert [3 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] Incyte Corp, Wilmington, DE USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-028
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [1] A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis
    Daver, Naval G.
    Kremyanskaya, Marina
    O'Connell, Casey
    Dao, Kim-Hien
    Oh, Stephen T.
    Gerds, Aaron T.
    Verstovsek, Srdan
    Erickson-Viitanen, Sue
    Zhou, Feng
    Assad, Albert
    Yacoub, Abdulraheem
    BLOOD, 2018, 132
  • [2] Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with myelofibrosis
    Yacoub, Abdulraheem
    Wang, Eunice
    Rampal, Raajit
    Borate, Uma
    Kremyanskaya, Marina
    Ali, Haris
    Hobbs, Gabriela
    O'Connell, Casey
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Burn, Timothy
    Daver, Naval
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 9 - 9
  • [3] Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis.
    Yacoub, Abdulraheem
    Wang, Eunice S.
    Rampal, Raajit K.
    Borate, Uma
    Kremyanskaya, Marina
    Ali, Haris
    Hobbs, Gabriela S.
    O'Connell, Casey
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Burn, Timothy C.
    Daver, Naval G.
    CANCER RESEARCH, 2021, 81 (13)
  • [4] Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF)
    Bose, Prithviraj
    Pemmaraju, Naveen
    Schroeder, Kurt
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Daver, Naval
    DiNardo, Courtney D.
    Alvarado, Yesid
    Yilmaz, Musa
    Huynh-Lu, Julie
    Qiao, Wei
    Wang, Xuemei
    Matamoros, Aurelio
    Zhou, Lingsha
    Pierce, Sherry
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [5] Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)
    Harrison, Claire N.
    Kiladjian, Jean Jacques
    Heidel, Florian H.
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Martino, Bruno
    Kindler, Thomas
    Lipka, Daniel B.
    Acharyva, Suddhasatta
    Gopalakrishna, Prashanth
    Ide, Susan
    Liu, Tracy
    Mu, Song
    Ribrag, Vincent
    BLOOD, 2015, 126 (23)
  • [6] Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis
    Gill, Harinder
    Au, Lester
    Leung, Garret Man Kit
    Tsai, Dorothy
    Yim, Rita
    Chin, Lynn
    Li, Vivian
    Lee, Paul
    Leung, Rock Yuk Yan
    Lee, Elaine
    Rienhoff, Hugh Young, Jr.
    Kwong, Yok Lam
    BLOOD, 2023, 142
  • [7] Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (RA) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
    Coleman, Morton
    Forero-Torres, Andres
    Ribrag, Vincent
    Chau, Ian
    DeMarini, Douglas James
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen T.
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BLOOD, 2020, 136
  • [9] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104).
    Oh, Stephen T.
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason R.
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    CANCER RESEARCH, 2021, 81 (13)
  • [10] A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
    Oh, Stephen
    Kiladjian, Jean-Jacques
    Palandri, Francesca
    Gotlib, Jason
    Mohan, Sanjay
    Ali, Haris
    Asatiani, Ekatherine
    Seguy, Francis
    Zhou, Feng
    Verstovsek, Srdan
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 111 - 112
12345